QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.107.040840v1 73/4/1064    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Puppala, D. Articles by Swanson, H. I. Search for Related Content PubMed PubMed Citation Articles by Puppala, D. Articles by Swanson, H. I.

Development of an Aryl Hydrocarbon Receptor Antagonist Using the Proteolysis-Targeting Chimeric Molecules Approach: A Potential Tool for Chemoprevention

Department of Molecular and Biomedical Pharmacology (D.P., H.I.S.), and Department of Pharmaceutical Sciences (H.L. and K.B.K.) University of Kentucky, Lexington, Kentucky

Activation of the aryl hydrocarbon receptor (AHR) by agonists and environmental contaminants like dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin) leads to many adverse biological effects, including tumor promotion. With this in mind, we propose that agents that block the AHR pathway may be therapeutically beneficial, particularly by exhibiting chemopreventive activities. In our current research, we have focused on the development of an AHR antagonist using a chemical genetic approach called PROTACS (PROteolysis-TArgeting Chimeric moleculeS). PROTACS is a novel approach of tagging small recognition sequences of a specific E3 ubiquitin ligase complex to a known ligand for the receptor of interest (AHR) for targeting its degradation. Here, we present the design and initial characterization of AHR targeting PROTACS (Apigenin-Protac) designed to degrade and inhibit the AHR in epithelial cells. Our results demonstrate the "proof of concept" of this approach in effectively blocking AHR activity in cultured cells.

Received for publication August 10, 2007.

Accepted for publication January 3, 2008.

Address correspondence to: Dr. Hollie Swanson, Department of Molecular and Biomedical Pharmacology, MS305, University of Kentucky College of Medicine, 800 Rose Street, Lexington, KY40536. E-mail: hswan{at}email.uky.edu

This article has been cited by other articles:

				S. Nair, V. D. Kekatpure, B. L. Judson, A. B. Rifkind, R. D. Granstein, J. O. Boyle, K. Subbaramaiah, J. B. Guttenplan, and A. J. Dannenberg UVR Exposure Sensitizes Keratinocytes to DNA Adduct Formation Cancer Prevention Research, October 1, 2009; 2(10): 895 - 902. [Abstract] [Full Text] [PDF]

				V. D. Kekatpure, A. J. Dannenberg, and K. Subbaramaiah HDAC6 Modulates Hsp90 Chaperone Activity and Regulates Activation of Aryl Hydrocarbon Receptor Signaling J. Biol. Chem., March 20, 2009; 284(12): 7436 - 7445. [Abstract] [Full Text] [PDF]

				D. Hughes, J. B. Guttenplan, C. B. Marcus, K. Subbaramaiah, and A. J. Dannenberg Heat Shock Protein 90 Inhibitors Suppress Aryl Hydrocarbon Receptor-Mediated Activation of CYP1A1 and CYP1B1 Transcription and DNA Adduct Formation Cancer Prevention Research, November 1, 2008; 1(6): 485 - 493. [Abstract] [Full Text] [PDF]